During the period of the health emergency caused by the COVID-19 pandemic, (SARS-CoV-2),
health care workers worldwide face a challenging scene in terms of patient care and safety. In search of an appropriate and beneficial strategy, healthcare workers across the system are working under pressure to make rapid decisions regarding clinical and pharmacological treatment, without the support of robust scientific evidence and with conclusive results, which can favor the use of inappropriate or ineffective therapies that can generate a negative impact on public health.
One of the most complex scientific activities during a health emergency is to determine whether a drug is a candidate to prevent or treat the disease effectively, and in turn, to establish whether the expected benefits outweigh the potential risks when used in patients. For this purpose, the use of the available scientific evidence must be made on pharmacological therapies which, due to the current situation, may change in a short time and may lead to poor quality information.
